List of Excipients in Branded Drug ALBUTEIN

ALBUTEIN Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Albutein is a human serum albumin solution marketed by Grifols and supplied in 5%, 20%, and 25% concentrations. Its excipient platform is conventional for plasma-derived albumin: sodium caprylate and N-acetyl-DL-tryptophan stabilize the protein during processing and storage, while sodium provides the principal tonicity and electrolyte load. The commercial opportunity is concentrated in supply reliability, differentiated albumin concentrations, lower-sodium formulations, improved container systems, recombinant albumin, and hospital procurement rather than in new use of the existing excipients.

The core Albutein formulation is mature and has limited apparent composition-of-matter patent leverage. Commercial protection depends more heavily on biologic manufacturing controls, plasma sourcing, viral-reduction processes, regulatory approvals, quality systems, and distribution capacity than on conventional pharmaceutical patents.

What is Albutein and how is it formulated?

Albutein is a sterile solution of albumin human derived from pooled human plasma. Grifols markets albumin human products in several concentrations, including Albutein 5%, Albutein 20%, and Albutein 25% [1].

Product	Albumin concentration	Primary clinical positioning	Formulation profile
Albutein 5%	50 mg/mL	Volume replacement and hypovolemia	Near-isotonic, larger infusion volume
Albutein 20%	200 mg/mL	Hyperoncotic volume expansion and hypoalbuminemia-related uses	Concentrated, lower infusion volume
Albutein 25%	250 mg/mL	Hyperoncotic applications	Highest albumin concentration and osmotic effect

The principal non-active formulation components are:

• Sodium caprylate, also known as sodium octanoate.
• N-acetyl-DL-tryptophan.
• Sodium and chloride or corresponding electrolyte content.
• Water for injection.

Albutein does not rely on an antimicrobial preservative. The product label states that albumin solutions are sterile and contain no preservative [1]. This is commercially relevant because preservative-free presentation supports intravenous hospital use but increases the importance of aseptic manufacturing, container integrity, and post-opening handling.

What do sodium caprylate and N-acetyl-DL-tryptophan do?

Sodium caprylate and N-acetyl-DL-tryptophan are stabilizing excipients used to protect albumin against heat-induced and oxidative degradation. Albumin is structurally sensitive to oxidation, aggregation, surface adsorption, and thermal stress. The stabilizer pair supports protein integrity during pasteurization and subsequent storage.

The excipients are not intended to create a pharmacologic effect. Their value is process and product protection:

Excipient	Primary function	Commercial significance
Sodium caprylate	Albumin stabilization and protection during heat treatment	Supports viral inactivation and shelf-life robustness
N-acetyl-DL-tryptophan	Stabilization against thermal and oxidative damage	Helps maintain albumin quality during pasteurization
Sodium chloride or equivalent electrolyte content	Osmolality and ionic environment	Affects sodium exposure and hospital selection
Water for injection	Vehicle	Requires sterile, pyrogen-controlled manufacturing

The excipient system must be evaluated as part of the complete biologic process. Changing the stabilizers can alter aggregation, oxidation, ligand binding, viscosity, filtration behavior, container compatibility, and impurity clearance.

What excipients are protected in Albutein?

The Albutein excipient combination is a longstanding pharmaceutical formulation approach rather than a new proprietary platform. No reliable basis exists to treat sodium caprylate or N-acetyl-DL-tryptophan as exclusive Albutein ingredients.

Human albumin products have historically used stabilizers such as caprylate and acetyltryptophan because albumin must withstand viral inactivation and storage without unacceptable loss of native structure. The technical barrier is not simply identifying the excipients. It is demonstrating that the formulation remains comparable across:

• Albumin purity and molecular-size distribution.
• Monomer, dimer, and aggregate levels.
• Oxidation and modification profiles.
• Ligand-binding activity.
• pH and osmolality.
• Particulate burden.
• Sterility and endotoxin.
• Viral safety.
• Container closure integrity.
• Stability through the labeled shelf life.

A competing product could use the same stabilizers without infringing a formulation patent if no enforceable patent claim covers the specific product, concentration, process, or combination. The more important barriers are regulatory comparability and manufacturing validation.

What is the FDA regulatory status of Albutein?

Albutein is an FDA-licensed biologic product, not a conventional small-molecule drug listed through the standard abbreviated new drug application pathway. FDA labeling identifies Albutein as albumin human and describes its indications, dosage, warnings, composition, manufacturing controls, and storage conditions [1].

The regulatory pathway creates several commercial consequences:

1. A competing product must obtain a biologics license or another legally available approval pathway.
2. Manufacturing sites and plasma-derived processes receive close regulatory review.
3. Product quality depends on donor screening, plasma testing, fractionation, purification, and viral-reduction steps.
4. A formulation change may require a supplement supported by comparability data.
5. Generic substitution concepts are less direct than for conventional injectable small molecules.

Albumin human is generally treated as a plasma-derived biologic. The principal competitive approval question is not whether a tablet-style generic can copy the excipients. It is whether the sponsor can produce a consistently comparable, safe, sterile, and clinically acceptable albumin product at commercial scale.

What is the Orange Book and Purple Book status of Albutein?

Albutein should not be analyzed like an Orange Book small-molecule product. The Orange Book primarily identifies approved drug products and associated patents and exclusivity for conventional drug applications. Biologic competition is generally analyzed through FDA biologic records, the Purple Book framework, licensing history, biologics exclusivity, and product-specific regulatory records [2].

A product-specific patent listing should not be assumed merely because Albutein is an FDA-approved biologic. The commercial estate is more likely to include:

• Manufacturing know-how.
• Plasma procurement arrangements.
• Process validation.
• Analytical methods.
• Quality-control specifications.
• Trade secrets.
• Facility approvals.
• Distribution agreements.
• Trademarks and brand recognition.

The absence of a prominent formulation patent does not remove market barriers. In plasma-derived products, manufacturing and supply-chain assets can be more difficult to replicate than a conventional formulation claim.

When does Albutein lose exclusivity?

Albutein is based on an established active ingredient, albumin human, with a long history of clinical use. Any original product exclusivity associated with the initial approval would have expired long ago. The practical question is therefore not the expiration of an original Albutein patent. It is whether a competitor can obtain approval and manufacture albumin human at an acceptable cost.

No single date should be treated as the end of Albutein’s commercial exclusivity. The product’s protection is layered:

Protection layer	Expected durability	Main source of competitive value
Original active-ingredient exclusivity	Expired	Albumin human is an established biologic
Core formulation patents	Limited or uncertain	Mature stabilizer technology
Manufacturing know-how	Continuing	Process control and yield
Plasma supply	Continuing	Donor network and fractionation capacity
Regulatory approval	Continuing	Licensed facilities and validated process
Brand and hospital contracts	Continuing	Procurement preference and supply history
Trademark rights	Continuing subject to maintenance	Albutein brand identity

A new entrant could face substantial development time even without a blocking patent. The timeline would include process development, analytical comparability, nonclinical and clinical justification, facility qualification, FDA review, and commercial inventory build.

What commercial opportunities exist in Albutein excipient strategy?

The strongest opportunities are formulation-adjacent and supply-chain oriented.

Lower-sodium albumin formulations

Sodium exposure can influence hospital selection, particularly in patients with fluid overload, cirrhosis, heart failure, renal impairment, or intensive-care needs. A lower-sodium formulation could offer a differentiated product if it preserves albumin stability and satisfies FDA requirements.

The opportunity has technical constraints. Sodium is part of the solution’s electrolyte environment, and reducing it can affect:

• Osmolality.
• Protein solubility.
• pH control.
• Container compatibility.
• Infusion tolerability.
• Stability under heat and storage.
• Labeling and clinical use instructions.

A lower-sodium albumin product would need more than a simple excipient substitution. It would require a full stability and comparability package.

Ready-to-use presentation and container improvements

Albumin is administered in hospitals, where handling efficiency affects procurement decisions. Commercially valuable improvements may include:

• Smaller-volume presentations for concentrated albumin.
• Flexible bags rather than glass bottles.
• Better overwrap and light protection.
• Reduced breakage during transport.
• Clearer dose markings.
• Latex-free components.
• Easier spike and administration systems.
• Unit-dose packaging for emergency and intensive-care use.

Container changes can create meaningful differentiation without changing the active ingredient. They also create regulatory and technical work involving extractables, leachables, adsorption, particulate generation, and container-closure integrity.

Extended in-use stability

An Albutein-style product is preservative-free. Hospitals may value validated in-use stability after container entry, particularly where a vial or bag is not fully consumed. A sponsor could seek differentiation through validated hold times, aseptic-transfer instructions, or smaller presentations that reduce waste.

Any such claim must be supported by microbial challenge or related in-use data, sterility assurance, particulate testing, and product stability. It cannot be based solely on the formulation’s chemical stability.

Recombinant or cell-culture-derived albumin

Recombinant human serum albumin could reduce dependence on human plasma and potentially simplify donor-related supply constraints. It may also support specialized applications in cell therapy, vaccine manufacturing, biologics production, and advanced drug delivery.

The challenge is cost and scale. Recombinant albumin must match the functional and structural attributes relevant to the intended use, including:

• Folding and disulfide structure.
• Oxidation state.
• Fatty-acid and ligand binding.
• Aggregation profile.
• Host-cell protein clearance.
• Endotoxin and bioburden control.
• Batch consistency.

Recombinant albumin may have stronger intellectual-property opportunities than traditional plasma-derived albumin. Claims could cover host cells, expression constructs, purification, stabilizer systems, high-concentration formulations, or use as a cell-culture supplement.

Albumin excipient use in biologics manufacturing

Albumin is itself a widely used excipient in biologic drug products, vaccines, cell therapies, and diagnostic reagents. A commercial strategy can target albumin as a process raw material rather than as an intravenous therapeutic.

Potential products include:

• Low-endotoxin recombinant albumin.
• Animal-origin-free albumin.
• Chemically defined albumin substitutes.
• Albumin optimized for cell therapy media.
• Albumin for viral-vector manufacturing.
• Albumin for mRNA and nanoparticle stabilization.
• Albumin for freeze-drying and cryopreservation.

These markets can support higher-margin specifications than conventional hospital albumin, particularly where customers require traceability, lot-to-lot consistency, and freedom from human- or animal-derived contaminants.

What formulation patents could protect an Albutein competitor?

A competitor seeking patent protection would have greater opportunity in a new formulation or manufacturing process than in the basic presence of albumin, sodium caprylate, or acetyltryptophan.

Potential claim areas include:

1. Albumin solutions with a defined low-sodium range.
2. Stabilizer systems that reduce oxidation or aggregation.
3. Albumin formulations with reduced caprylate or tryptophan levels.
4. High-concentration albumin products with improved viscosity.
5. Albumin formulations compatible with flexible polymer containers.
6. Lyophilized or ready-to-reconstitute albumin.
7. Albumin combined with specific electrolytes or buffering systems.
8. Recombinant albumin with defined post-translational or oxidation profiles.
9. Manufacturing methods that improve yield or reduce aggregate formation.
10. Use of albumin as a stabilizer for other biologic active ingredients.

Patentability would depend on novelty, non-obviousness, enablement, written description, and claim scope. Broad claims covering albumin plus conventional stabilizers would face substantial prior-art risk. Narrow claims tied to measured attributes, defined concentration ranges, specific process conditions, or unexpected stability results would have a stronger prosecution position.

What patent litigation and Paragraph IV risks affect Albutein?

Traditional Paragraph IV litigation is generally associated with abbreviated new drug applications referencing listed small-molecule products in the Orange Book. It is not the primary competitive mechanism for albumin human biologics.

The more relevant risks are:

• Patent litigation over recombinant albumin production.
• Disputes involving chromatography, viral inactivation, or purification.
• Trade-secret claims related to plasma fractionation.
• Biosimilar or biologic-licensing disputes.
• Contract litigation involving plasma supply.
• Trademark disputes involving Albutein branding.
• Regulatory challenges to product comparability or interchangeability.

A biosimilar-style challenge would require a licensed reference product and an appropriate regulatory pathway. Albumin’s long clinical history may reduce clinical development requirements in some scenarios, but it does not eliminate the need to establish product quality and manufacturing consistency.

Which companies compete with Albutein?

The competitive landscape includes other albumin human manufacturers and suppliers of recombinant or specialty albumin. Relevant competitors may include:

• CSL Behring, with Alburex and related albumin products in selected markets.
• Kedrion, with human albumin products.
• Octapharma, with human albumin products in certain jurisdictions.
• Takeda, through plasma-derived product operations in relevant markets.
• China-based plasma fractionators serving domestic and selected international markets.
• Recombinant albumin suppliers serving bioprocessing and research markets.

Availability varies by country, product concentration, regulatory approval, and hospital procurement channel. The most important competitive variables are often supply continuity, price, concentration options, contract terms, and clinical familiarity rather than excipient novelty.

How does Albutein compare with competing albumin products?

Criterion	Albutein	Competing plasma-derived albumin	Recombinant albumin
Source	Human plasma	Human plasma	Cell-culture production
Core stabilizer approach	Caprylate and N-acetyl-DL-tryptophan	Often similar or related stabilizer systems	Product-dependent
Supply constraint	Plasma availability and fractionation capacity	Same structural constraint	Fermentation and purification capacity
Main regulatory burden	Plasma safety and biologic manufacturing	Plasma safety and biologic manufacturing	Manufacturing consistency and comparability
Patent leverage	Likely process and know-how focused	Similar	Potentially stronger platform claims
Hospital adoption	Established product familiarity	Depends on market	Limited for therapeutic replacement unless specifically approved
Bioprocessing opportunity	Therapeutic and excipient use	Therapeutic and excipient use	Stronger fit for animal-origin-free applications

Albutein’s competitive position is strongest where Grifols can combine regulatory continuity, supply reliability, and broad concentration availability. A competitor would need to offer a measurable advantage, such as lower acquisition cost, improved supply, smaller waste profile, lower sodium, or a validated specialty use.

What manufacturing and intellectual-property barriers exist?

The principal barrier is access to qualified plasma and the ability to convert it into a consistent albumin product. Key manufacturing requirements include:

• Donor eligibility and infectious-disease testing.
• Plasma pooling controls.
• Ethanol fractionation or equivalent separation.
• Purification and polishing.
• Viral inactivation and removal.
• Sterile filtration.
• Aseptic filling.
• Stability testing.
• Container-closure validation.
• Pharmacopoeial compliance.

The excipient strategy must be integrated with the manufacturing process. Sodium caprylate and N-acetyl-DL-tryptophan may affect filtration, recovery, protein interactions, and viral-inactivation conditions. Removing or replacing them can create process changes that are more consequential than the excipient label suggests.

From an IP perspective, trade secrets may have greater practical value than patents in areas such as yield optimization, impurity clearance, process controls, and lot-release analytics. Patents remain useful for recombinant production, specialty formulations, and differentiated packaging.

What revenue exposure and market opportunities are relevant?

Albutein revenue is exposed to several factors:

• Hospital demand for volume expansion and critical-care use.
• Albumin use in cirrhosis and related complications.
• Demand for 5%, 20%, and 25% concentrations.
• Plasma collection volumes.
• Manufacturing downtime.
• Public and private hospital tenders.
• Pricing controls and reimbursement policy.
• Competition from other albumin human products.
• Clinical debate over albumin versus crystalloid or synthetic colloid alternatives.

Commercial opportunities are strongest in markets with constrained albumin supply, high critical-care utilization, and fragmented procurement. A differentiated product can compete through supply assurance, not only through formulation.

For investors and licensors, the most valuable assets are likely to be:

1. An approved albumin manufacturing platform.
2. A dependable plasma supply network.
3. A lower-sodium or low-waste product with clinical utility.
4. A recombinant albumin platform with bioprocessing customers.
5. A validated container or administration system.
6. Contract access to major hospital systems.
7. Regulatory approvals in markets with limited local supply.

Key Takeaways

• Albutein is a plasma-derived human albumin biologic marketed in 5%, 20%, and 25% concentrations.
• Sodium caprylate and N-acetyl-DL-tryptophan are stabilizing excipients, not primary therapeutic agents.
• Albutein’s formulation technology is mature, so broad patent protection around the basic excipient combination is likely limited.
• The strongest barriers are plasma supply, manufacturing validation, viral safety, regulatory approval, and quality systems.
• Orange Book analysis is less relevant than biologic approval, Purple Book-related competition, biologic exclusivity, and manufacturing rights.
• Commercial opportunities include lower-sodium albumin, improved containers, reduced waste, validated in-use stability, recombinant albumin, and albumin for advanced bioprocessing.
• A competitor is more likely to win through supply reliability, price, packaging, or a specialty formulation than through a simple excipient substitution.
• Recombinant albumin offers the clearest long-term platform opportunity for animal-origin-free biologics manufacturing and cell-therapy applications.

FAQs

Is sodium caprylate in Albutein an active pharmaceutical ingredient?

No. Sodium caprylate is an excipient used to stabilize albumin during processing and storage. It is not the therapeutic active ingredient.

Can a manufacturer remove N-acetyl-DL-tryptophan from an albumin product?

A manufacturer can develop a different formulation, but removal would require evidence that the product maintains acceptable stability, purity, safety, and quality through manufacturing and shelf life. The change would require regulatory justification.

Does Albutein have a patent blocking albumin human competitors?

The main competitive barriers are not necessarily a single blocking patent. Albumin human is an established biologic, and competition depends heavily on manufacturing capability, plasma access, regulatory approval, and supply contracts.

Is recombinant albumin interchangeable with Albutein?

No automatic interchangeability should be assumed. Recombinant albumin and plasma-derived albumin require product-specific regulatory evaluation, even if both contain human serum albumin.

Which Albutein concentration has the greatest formulation opportunity?

The 20% and 25% products offer the clearest opportunity for high-concentration, lower-volume, lower-sodium, and reduced-waste differentiation. The 5% product may offer stronger opportunity in container design and infusion logistics.

References

1. U.S. Food and Drug Administration. (2023). Albutein 5%, albumin human injection, solution: Prescribing information. Grifols Biologicals LLC.
2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
3. U.S. Food and Drug Administration. (2020). Product-specific guidances for biosimilar development. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla
4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Albumin human monograph.
5. World Health Organization. (2009). WHO Expert Committee on Biological Standardization: Recommendations for the production, control and regulation of human plasma for fractionation. World Health Organization.
6. Grifols, S.A. (2024). Human albumin products and plasma-derived medicines. https://www.grifols.com/